M&A from the Heart

from Running Through Walls Hosted by Venrock, a venture capital firm

Venrock partner Camille Samuels speaks with Corvidia co-founders Ram Aiyar and Michael Davidson about Corvidia's recent acquisition by Novo Nordisk, just four years after its founding. They discuss how inflammation contributes to cardiovascular disease – the number one killer in the United States – and how their drug Ziltivekimab "Zilti" is proving to be a successful therapy. Aiyar and Davidson share their experiences and advice for other companies exploring a sale, including always being ready for Plan B (or C), maintaining positive relationships, and not rushing any deals. They also discuss why the cardiovascular space is becoming increasingly appealing to entrepreneurs and investors when it was previously avoided.

Episode details come from the podcast's RSS feed.

Embed this episode

Attribution link and audio player

Ready to play

M&A from the Heart

0:00 33:03

No transcript yet.

Requests help us decide what to transcribe next.

Share this episode

Similar podcasts

CISO Perspectives (public) N2K Networks This season on CISO Perspectives, host Kim Jones explores some of the challenges of leading through uncertainty. We explore the complexity of the changing nature of regulation and working with the federal government, the evolution of privacy and fraud, and how emerging technologies like AI and quantum computing are changing cyber. When you don’t know what questions to ask, you’re afraid to ask, or don’t know who to ask, CISO Perspectives provides the foundation for learning in this brave new world.

Frequently asked questions

How long is this episode of Running Through Walls?

This episode is 33 minutes long.

When was this Running Through Walls episode published?

This episode was published on October 14, 2020.

Can I download this Running Through Walls episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.